NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. is investigating potential claims against Aptinyx, Inc. (NYSE: APTX) on behalf of Aptinyx stockholders. Our investigation concerns whether Aptinyx has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
Aptinyx completed its IPO on June 21, 2018, offering shares at $16.00 per share for net proceeds of $92.2 million. Aptinyx is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of synthetic molecules for the treatment of brain and nervous system disorders. NYX-2925 is an NDMA receptor modulator currently in Phase 2 clinical development.
On January 16, 2019, Aptinyx announced that its drug, NYX-2925, did not achieve statistically significant separation from the placebo on a primary end point in its phase 2 trial.
On this news, shares of Aptinyx fell $11.85, or 67%, to close at $5.98 per share. The stock has yet to recover and currently trades at around $3.28, a 79.5% decline from its IPO price
If you purchased or otherwise acquired Aptinyx shares pursuant to and/or traceable to the IPO and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Aptinyx please go to https://bespc.com/aptx. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.